Marksans Pharma has informed that it enclosed press release regarding the final approval of the Company’s Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx) from USFDA. This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.
The above information is a part of company’s filings submitted to BSE.
